Company Description
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases.
It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia.
It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726.
NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Hyung-Heon Kim |
Contact Details
Address: 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 United States | |
Phone | 857 702 9600 |
Website | neurobopharma.com |
Stock Details
Ticker Symbol | NRBO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001638287 |
CUSIP Number | 64132R107 |
ISIN Number | US64132R4048 |
Employer ID | 47-2389984 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Hyung-Heon Kim | Chief Executive Officer, President and Director |
Marshall H. Woodworth | Chief Financial Officer |
Dr. Mi-Kyung Kim | Chief Scientific Officer |
Robert Homolka | Senior Vice President of Clinical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 7, 2024 | 8-K | Current Report |
Sep 30, 2024 | 8-K | Current Report |
Sep 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Sep 19, 2024 | 8-K | Current Report |
Aug 21, 2024 | DEF 14A | Other definitive proxy statements |
Aug 14, 2024 | 10-Q | Quarterly Report |
Aug 14, 2024 | 8-K | Current Report |
Aug 13, 2024 | 8-K | Current Report |
Aug 7, 2024 | PRE 14A | Other preliminary proxy statements |
Aug 6, 2024 | 8-K | Current Report |